Lannett Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LANNETT
LANNETT has one hundred and thirty-three approved drugs.
There are two tentative approvals on LANNETT drugs.
Summary for Lannett
| US Patents: | 0 |
| Tradenames: | 98 |
| Ingredients: | 95 |
| NDAs: | 133 |
| Patent Litigation for Lannett: | See patent lawsuits for Lannett |
| PTAB Cases with Lannett as petitioner: | See PTAB cases with Lannett as petitioner |
Drugs and US Patents for Lannett
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lannett Co Inc | HYDROCHLOROTHIAZIDE | hydrochlorothiazide | TABLET;ORAL | 084325-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Lannett Co Inc | DOXYCYCLINE | doxycycline | TABLET;ORAL | 065285-002 | Dec 8, 2005 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Lannett | PHENTERMINE HYDROCHLORIDE | phentermine hydrochloride | CAPSULE;ORAL | 087022-001 | Feb 3, 1983 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for LANNETT drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
